Literature DB >> 23589499

MAO inhibitory activity of 2-arylbenzofurans versus 3-arylcoumarins: synthesis, in vitro study, and docking calculations.

Giulio Ferino1, Enzo Cadoni, Maria João Matos, Elias Quezada, Eugenio Uriarte, Lourdes Santana, Santiago Vilar, Nicholas P Tatonetti, Matilde Yáñez, Dolores Viña, Carmen Picciau, Silvia Serra, Giovanna Delogu.   

Abstract

Monoamine oxidase (MAO) is an important drug target for the treatment of neurological disorders. Several 3-arylcoumarin derivatives were previously described as interesting selective MAO-B inhibitors. Preserving the trans-stilbene structure, a series of 2-arylbenzofuran and corresponding 3-arylcoumarin derivatives were synthesized and evaluated as inhibitors of both MAO isoforms, MAO-A and MAO-B. In general, both types of derivatives were found to be selective MAO-B inhibitors, with IC50 values in the nano- to micromolar range. 5-Nitro-2-(4-methoxyphenyl)benzofuran (8) is the most active compound of the benzofuran series, presenting MAO-B selectivity and reversible inhibition (IC50 =140 nM). 3-(4'-Methoxyphenyl)-6-nitrocoumarin (15), with the same substitution pattern as that of compound 8, was found to be the most active MAO-B inhibitor of the coumarin series (IC50 =3 nM). However, 3-phenylcoumarin 14 showed activity in the same range (IC50 =6 nM), is reversible, and also severalfold more selective than compound 15. Docking experiments for the most active compounds into the MAO-B and MAO-A binding pockets highlighted different interactions between the derivative classes (2-arylbenzofurans and 3-arylcoumarins), and provided new information about the enzyme-inhibitor interaction and the potential therapeutic application of these scaffolds.
Copyright © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23589499     DOI: 10.1002/cmdc.201300048

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  9 in total

1.  MAO inhibitory activity of bromo-2-phenylbenzofurans: synthesis, in vitro study, and docking calculations.

Authors:  G L Delogu; F Pintus; L Mayán; M J Matos; S Vilar; J Munín; J A Fontenla; G Hripcsak; F Borges; D Viña
Journal:  Medchemcomm       Date:  2017-07-07       Impact factor: 3.597

2.  Novel 2-pheynlbenzofuran derivatives as selective butyrylcholinesterase inhibitors for Alzheimer's disease.

Authors:  Amit Kumar; Francesca Pintus; Amalia Di Petrillo; Rosaria Medda; Paola Caria; Maria João Matos; Dolores Viña; Enrico Pieroni; Francesco Delogu; Benedetta Era; Giovanna L Delogu; Antonella Fais
Journal:  Sci Rep       Date:  2018-03-13       Impact factor: 4.379

Review 3.  3-Phenylcoumarins as a Privileged Scaffold in Medicinal Chemistry: The Landmarks of the Past Decade.

Authors:  Maria J Matos; Eugenio Uriarte; Lourdes Santana
Journal:  Molecules       Date:  2021-11-08       Impact factor: 4.411

4.  Coumarin-Resveratrol-Inspired Hybrids as Monoamine Oxidase B Inhibitors: 3-Phenylcoumarin versus trans-6-Styrylcoumarin.

Authors:  Marco Mellado; César González; Jaime Mella; Luis F Aguilar; Ismail Celik; Fernanda Borges; Eugenio Uriarte; Giovanna Delogu; Dolores Viña; Maria J Matos
Journal:  Molecules       Date:  2022-01-29       Impact factor: 4.411

Review 5.  Natural source, bioactivity and synthesis of 3-Arylcoumarin derivatives.

Authors:  Qiang Zhang; Yu-Hang Miao; Teng Liu; Yin-Ling Yun; Xiao-Ya Sun; Tao Yang; Jie Sun
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

6.  Structure-Activity Relationship Analysis of 3-Phenylcoumarin-Based Monoamine Oxidase B Inhibitors.

Authors:  Sanna Rauhamäki; Pekka A Postila; Sanna Niinivehmas; Sami Kortet; Emmi Schildt; Mira Pasanen; Elangovan Manivannan; Mira Ahinko; Pasi Koskimies; Niina Nyberg; Pasi Huuskonen; Elina Multamäki; Markku Pasanen; Risto O Juvonen; Hannu Raunio; Juhani Huuskonen; Olli T Pentikäinen
Journal:  Front Chem       Date:  2018-03-02       Impact factor: 5.221

7.  Synthesis and biological evaluation of 3-arylcoumarin derivatives as potential anti-diabetic agents.

Authors:  Yuheng Hu; Bing Wang; Jie Yang; Teng Liu; Jie Sun; Xiaojing Wang
Journal:  J Enzyme Inhib Med Chem       Date:  2019-12       Impact factor: 5.051

8.  Structural Insight of New Butyrylcholinesterase Inhibitors Based on Benzylbenzofuran Scaffold.

Authors:  Giovanna L Delogu; Antonella Fais; Francesca Pintus; Chinmayi Goyal; Maria J Matos; Benedetta Era; Amit Kumar
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-02

9.  Synthesis and biological evaluation of 2-arylbenzofuran derivatives as potential anti-Alzheimer's disease agents.

Authors:  Yinling Yun; Yuhang Miao; Xiaoya Sun; Jie Sun; Xiaojing Wang
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.